Merck adds $300M, 180 jobs at NC plant; Novartis yanks pre-pandemic vaccine app;

> Color North Carolina pleased. Merck plans to invest an additional $300 million in a vaccine plant in Durham, N.C., expanding it beyond its original scope.

> When the interview subject is adversity, who better to question than Schering-Plough's Fred Hassan, who's seen his share this year? Report

> Bavarian Nordic says that an interim analysis of two clinical trials of its experimental breast cancer vaccine shows that the therapy appears to be well tolerated and immunogenic. Report

> Faced with a looming deadline to provide more data on the pre-pandemic vaccine Aflunov, Novartis Vaccines and Diagnostics has pulled its application for centralized marketing authorization from the European Medicines Agency. Report

> When British health officials weighed the benefits of the two cervical cancer vaccines, they concluded that Cervarix from GlaxoSmithKline provided the best value for the money. Report

> British ministers have ordered a review of antipsychotics, which have been linked to an increased risk of death in elderly patients with dementia. Report

> More government watchdogs appear to be boarding the Paxil investigation train. The Justice Department is coordinating a probe that includes Colorado's Justice folks and the Boston U.S. attorney's office. Report

And Finally... Thirty-two thousand veterans will soon find letters about Chantix in their mailboxes. Chantix report